Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome.
作者信息
Reschke Robin, Richter Jasmin, Enk Alexander H, Hassel Jessica C
机构信息
Medical Faculty Heidelberg, Department of Dermatology and National Center for Tumor Diseases, Heidelberg University, Heidelberg, Germany.
German Cancer Consortium, Core Center Heidelberg, Heidelberg, Germany.
出版信息
JAMA Dermatol. 2025 Jan 1;161(1):104-105. doi: 10.1001/jamadermatol.2024.4445.
Abstract
摘要
相似文献
1
Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome.在使用刺猬抑制剂后或作为基底细胞痣综合征的一线治疗使用抗PD1阻断剂。
JAMA Dermatol. 2025 Jan 1;161(1):104-105. doi: 10.1001/jamadermatol.2024.4445.
2
Basal cell nevus syndrome (Gorlin syndrome): genetic insights, diagnostic challenges, and unmet milestones.基底细胞痣综合征（戈林综合征）：遗传学见解、诊断挑战及未达成的里程碑
Pathophysiology. 2018 Jun;25(2):77-82. doi: 10.1016/j.pathophys.2017.12.004. Epub 2018 Jan 31.
3
Vismodegib hedgehog-signaling inhibition and treatment of basal cell carcinomas as well as keratocystic odontogenic tumors in Gorlin syndrome.维莫德吉抑制Hedgehog信号通路及治疗基底细胞癌和戈林综合征中的牙源性角化囊性瘤。
Ann Maxillofac Surg. 2015 Jan-Jun;5(1):14-9. doi: 10.4103/2231-0746.161049.
4
Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series.维莫德吉或索尼德吉持续抑制 Gorlin 综合征相关基底细胞癌：病例系列。
Curr Oncol. 2023 Oct 16;30(10):9156-9167. doi: 10.3390/curroncol30100661.
5
Gorlin syndrome (nevoid basal cell carcinoma syndrome): update and literature review.戈林综合征（痣样基底细胞癌综合征）：最新进展与文献综述
Pediatr Int. 2014 Oct;56(5):667-74. doi: 10.1111/ped.12461.
6
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023.欧洲基于共识的多学科指南：基底细胞癌的诊断和治疗——2023 年更新版。
Eur J Cancer. 2023 Oct;192:113254. doi: 10.1016/j.ejca.2023.113254. Epub 2023 Jul 28.
7
Topical application of the Hedgehog inhibitor patidegib in patients with Gorlin syndrome: a phase II trial.在戈林综合征患者中局部应用刺猬蛋白抑制剂帕替吉布：一项II期试验。
Br J Dermatol. 2025 Mar 18;192(4):611-617. doi: 10.1093/bjd/ljae444.
8
Acquisition of Drug Resistance in Basal Cell Nevus Syndrome Tumors through Basal to Squamous Cell Carcinoma Transition.基底细胞痣综合征肿瘤通过基底细胞向鳞状细胞癌转化获得耐药性。
J Invest Dermatol. 2024 Jun;144(6):1368-1377.e6. doi: 10.1016/j.jid.2023.10.040. Epub 2023 Dec 28.
9
Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome).痣样基底细胞癌综合征（戈林综合征）。
Head Neck Pathol. 2016 Jun;10(2):119-24. doi: 10.1007/s12105-016-0706-9. Epub 2016 Mar 14.
10
Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.接受抗程序性死亡-1 治疗转移性黑色素瘤患者的基底细胞癌和鳞状细胞癌的发病率。
J Immunother. 2018 Sep;41(7):343-349. doi: 10.1097/CJI.0000000000000237.
引用本文的文献
1
Prognostic Biomarkers in Evolving Melanoma Immunotherapy.进展期黑色素瘤免疫治疗中的预后生物标志物
Am J Clin Dermatol. 2025 Mar;26(2):213-223. doi: 10.1007/s40257-024-00910-y. Epub 2024 Dec 21.
本文引用的文献
1
Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade.基底细胞癌的免疫微环境与 PD-1/LAG-3 联合阻断后的肿瘤消退
J Immunother Cancer. 2023 Dec 14;11(12):e007463. doi: 10.1136/jitc-2023-007463.
2
Immunotherapy and Its Timing in Advanced Basal Cell Carcinoma Treatment.晚期基底细胞癌治疗中的免疫疗法及其时机选择
Dermatol Pract Concept. 2023 Oct 1;13(4):e2023252. doi: 10.5826/dpc.1304a252.
3
A guideline for the clinical management of basal cell naevus syndrome (Gorlin-Goltz syndrome).《基底细胞痣综合征（痣样基底细胞癌综合征）临床管理指南》。
Br J Dermatol. 2022 Feb;186(2):215-226. doi: 10.1111/bjd.20700. Epub 2021 Nov 8.
4
Effective anti-programmed death-1 therapy in a SUFU-mutated patient with Gorlin-Goltz syndrome.SUFU 突变型 Gorlin-Goltz 综合征患者行有效抗程序性死亡-1 治疗。
Br J Dermatol. 2018 Sep;179(3):747-749. doi: 10.1111/bjd.16607. Epub 2018 Jun 26.
5
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.抑制基底细胞痣综合征患者的 hedgehog 通路。
N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.
Zotero 插件